Google
ABUS — ARBUTUS BIOPHARMA CORP (Healthcare >> Biotechnology)
ABUS FAQ
What is ABUS's P/E ratio?
ARBUTUS BIOPHARMA CORP (ABUS) currently trades at a P/E ratio of 4.87.
What is ABUS's ROE?
ARBUTUS BIOPHARMA CORP reports a Return on Equity (ROE) of 61.77%.
What is ABUS's dividend yield?
ARBUTUS BIOPHARMA CORP offers a dividend yield of 0.00%.
What is ABUS's Deepscope Quality Score?
Deepscope rates ABUS's overall financial quality at 69 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy ABUS?
Deepscope's AI Timing Score for ABUS is 27 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does ABUS belong to?
ARBUTUS BIOPHARMA CORP is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange.
|
USD 4.25
Price
-0.10
(-2.30%)
Day Change
|
|
|---|
ABUS, the overall quality is ok ( Quality = 69) and the timing to buy is ...(Sign In to See)...
Loading chart...
- Signal
- NEUTRAL
- Signal Description
- Company financial health is OK
- Reason
-
Acceleration of ROE growth rate is below our criteria.
Historical ROE is relatively low
Acceleration of ROA growth rate is below our criteria.
Historical net profit margin is relatively low.
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Lorem ipsum dolor sit amet
In details, quality factors are not quite good , financial health is not good , and ability to make profit is ok , ...
| Quality Factors |
|
51% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 93 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 4.25 |
| PBV / Sector |
3.23 / 4.63
|
| Earning Per Share | 0.81 |
| PE / Sector |
4.87 / 17.43
GREAT
|
| PEG or PE/Growth / Sector |
-0.20 / 0.53
|
| Average 1M Daily Value |
6.51 M
|
| Average 1W Daily Value |
5.34 M
GREAT
|
| Timing Factors |
|
28% |
| Financial Health |
|
41% |
| Ability to Make Profit |
|
68% |
| Return to Investors |
|
4% |
| Registration Details |
| Analyze Date | 2026-06-06 09:08:25 |
| Symbol | ABUS |
| Name | ARBUTUS BIOPHARMA CORP |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 197.54 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 839.54 / 8,857.28 |
| News, Concensus, ... |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 701 Veterans Circle, Warminster, PA, United States, 18974
Phone: 267 469 0914
Website: https://www.arbutusbio.com
Sector: Healthcare >> Biotechnology
Description: Arbutus Biopharma Corporation, a clinical-stage biopharmaceutical company, develops novel therapeutics for infectious disease in the United States. Its chronic Hepatitis B virus product pipeline comprises Imdusiran, conjugated GalNAc, subcutaneously-delivered RNAi therapeutic product candidate which is in phase 2a clinical trials that suppresses all HBV antigens, including HBsAg expression; and AB-101, an oral PD-L1 inhibitor, which is in phase 1a/1b clinical trial that has the potential to reawaken patients' HBV-specific immune response by inhibiting PD-L1. The company has licensing agreement with Alnylam Pharmaceuticals, Inc. to develop and commercialize products with LNP delivery technology. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation was incorporated in 2005 is headquartered in Warminster, Pennsylvania.
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
